Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
D000208:Acute Disease; D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use; D000077209:Decitabine; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male
D000970:Antineoplastic Agents; D003561:Cytarabine; D000077209:Decitabine; D001374:Azacitidine